ResearcherVilnius UniversityActive in the last 2 years

Skaistė Tulytė

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2288-8402; OpenAlex author ID A5071964732. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 paper · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper

Papers 3

Long-Term Response and Survival With Liposomal Irinotecan and Fluorouracil in a Patient With Locally Advanced Pancreatic Ductal Adenocarcinoma: A Case Report. Co-author DOI 10.7759/cureus.113923 ↗
Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or gemcitabine. Co-author DOI 10.1016/j.intimp.2023.109722 ↗
The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.21873/anticanres.15794 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Liutauras Gumbys · 1 shared paper, 2026 · strength 0.50
- Paper Long-Term Response and Survival With Liposomal Irinotecan and Fluorouracil in a Patient With Locally Advanced Pancreati… DOI 10.7759/cureus.113923 ↗
Audrius Šileikis · 2 shared papers, 2022–2023 · strength 0.37
- Paper Prognostic value of circulating T-lymphocyte subsets in advanced pancreatic cancer patients treated with mFOLFIRINOX or… DOI 10.1016/j.intimp.2023.109722 ↗
- Paper The Effects of Treatment on Peripheral Blood Immune Cell Profile in Pancreatic Ductal Adenocarcinoma (PDAC). DOI 10.21873/anticanres.15794 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.